Positive AGM Statement
RUA have provided a recent flurry of positive news, including an update on RUA Vascular division’s products and the recovery in elective surgical procedures in the US and Europe.The AGM update paints a recovering picture of the orders and therefore revenues at its RUA Medical Devices division. The recovery in elective surgical procedures and orders from its largest customer are expected to result in shipments that will average around 90% of pre-pandemic levels over the next three months. RUA Medical Devices has received orders in five out of the last eight weeks at higher levels than the pre-pandemic weekly average value.
There is also progress for RUA Vascular‘s Elast-Eon-sealed large diameter sealed vascular grafts and patches, as the critical ‘design freeze’ stage has been reached for the graft. Achieving the leak and permeability characteristics of market-leading grafts without animal products now clears the way for regulatory testing to complete in early 2021.
With the tangible progress in RUA’s surgical grafts and patches, we are getting closer to increasing our valuation, but for now make no changes to financials. We still value RUA Life Sciences at £99.3m or 676p per share.
Johnson & Johnson is a holding company engaged in the research and development, manufacture and sale of a range of products in the health care field. The company has three business segments: Consumer, which includes a range of products focused on personal healthcare used in the beauty, over-the-counter pharmaceutical, baby care, oral care, women's health and wound care markets; Pharmaceutical, which is focused on six therapeutic areas: immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism and pulmonary hypertension; and Medical Devices, which includes products used in the orthopaedic, surgery, interventional solutions, and eye health fields.
Equity Development enables companies to become better understood and supported by investors. Since our launch in 1996 we have consistently focused on helping our clients improve their communication and relationships with both existing and potential shareholders. Our clients have come from a wide variety of sectors and domiciles, are both private and quoted and range in size from micro-cap to $multi-billions. We offer free access to company research notes written by experienced analysts. These notes include detailed forecasts, financial models and a fair value. We host regular Private Investor Forums at which investors have the opportunity to hear company directors present, and to ask questions. These are free to attend. We broadcast live Webinars with company management that include active Q&A. We also make the recordings available online. We arrange face to face meetings between private investors and company management. We are active users of Twitter, commenting daily on company news, share price moves, Directors’ Dealings, Equity Development Research Notes & Events.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.